Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 17, 2009

Cangene to Use Upfront’s Platform to Produce Antibodies from Plasma

  • Cangene obtained rights to use Upfront Chromatography’s technology for the production of therapeutic human antibody products from human plasma. Upfront reports that its Rhobust® 2nd Generation Expanded Bed Adsorption (EBA) platform addresses the main drawbacks haunting the classical Cohn ethanol precipitation process: poor product yields, low productivity, and usage of ethanol that can destroy biological activity of some proteins.

    The Rhobust 2nd Generation EBA chromatography system accommodates unclarified and unstable raw materials and operates at high flow rates. It creates no back pressure, which is a typical shortcoming of packed-bed chromatography, the firm points out.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »